In this Letter on page 353, the words ‘substrate Hsp90’ should have been included in this sentence as follows: “Likewise, histone deacetylase inhibitors, including FDA-approved SAHA, are promising anti-cancer drugs whose actions involve hyperacetylation of histone and select non-histone targets including HDAC6 substrate Hsp90, thus indirectly inhibiting Hsp90 (ref. 21)”. This has been corrected in the online versions.
Additional information
The online version of the original article can be found at 10.1038/nature14430
Rights and permissions
About this article
Cite this article
Alexandrova, E., Yallowitz, A., Li, D. et al. Correction: Corrigendum: Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment. Nature 527, 398 (2015). https://doi.org/10.1038/nature15720
Published:
Issue Date:
DOI: https://doi.org/10.1038/nature15720
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.
